Niclas Stiernholm, PhD

Executive-in-Residence

Dr. Niclas Stiernholm, currently an independent consultant, has decades of executive experience in the biotechnology industry, most recently as President and Chief Executive Officer of Trillium Therapeutics. Under his direction and leadership, Trillium grew from one to 65 employees, raised over $200M in the capital markets, transitioned from a discovery-based academic spin-out venture to a clinical-stage immune-oncology company, listed on both Nasdaq and the Toronto Stock Exchange. Dr. Stiernholm joined Trillium from YM BioSciences where he was Executive Vice President and Chief Scientific Officer, when the company successfully completed its Initial Public Offering (IPO). Dr. Stiernholm has also served on numerous boards of directors and is currently director of Vasomune Therapeutics. He received his PhD in immunology from the University of Toronto, where he also completed his postdoctoral training.

Other Team Members

Connie Chen, PhD

Senior Director, Strategy and Corporate Development
Connie-Chen-img

Matthew Ward, MBA

Investment Analyst